Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering
I'm PortAI, I can summarize articles.
Xenetic Biosciences reported a 67.2% increase in Q3 2025 revenue to $1.0 million, driven by increased royalty revenue from a sublicense agreement with Takeda Pharmaceuticals. The company ended the quarter with $4.1 million in cash and completed a $3.9 million public offering. Xenetic continues to advance its DNase I program and collaborate with institutional partners. This summary is based on AI-generated content by Public Technologies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments